Showing 621 - 640 results of 229,132 for search '(( a a decrease ) OR ( 5 ((((we decrease) OR (a decrease))) OR (mean decrease)) ))', query time: 2.10s Refine Results
  1. 621
  2. 622
  3. 623
  4. 624
  5. 625
  6. 626
  7. 627
  8. 628
  9. 629
  10. 630
  11. 631
  12. 632
  13. 633

    Decrease in number of activated macrophages in demyelinated nerves subjected to 1hr ES. by Nikki A. McLean (643606)

    Published 2014
    “…Note: ES results in a significant decrease in the ED-1 IF 10d post-LPC (5d post-ES; K) and 12d post-LPC (7d post-ES; N) relative to LPC only in a pattern suggestive of movement toward lateral edges and egress (arrow). …”
  14. 634
  15. 635

    The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits - Fig 4 by Jin Zhou (90734)

    Published 2017
    Subjects: “…prolyl 4- hydroxylase inhibitor GSK 360A decreases post-stroke brain injury…”
  16. 636

    Drugs which cluster on the 'anxiolytic' group decrease 5-HT turnover in the brain. by Caio Maximino (100467)

    Published 2014
    “…Points represent means and error bars represent standard errors. A negative correlation is found between the decrease in serotonin turnover and the increase in time on white produced by a drug (r<sup>2</sup> = 0.5688, p = 0.0073).…”
  17. 637
  18. 638

    Activation of mGluR5 site-specifically decreases spine density in the nucleus accumbens. by Kellie S. Gross (3115299)

    Published 2016
    “…<p>(A) Schematic representation of injection sites of either vehicle (open circles) or CHPG (filled circles). …”
  19. 639

    The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits - Fig 6 by Jin Zhou (90734)

    Published 2017
    Subjects: “…prolyl 4- hydroxylase inhibitor GSK 360A decreases post-stroke brain injury…”
  20. 640

    Eltrombopag markedly decreases levels of ROS in MOLM14 cells. by Anna Kalota (7415)

    Published 2015
    “…B) Graphic presentation of ROS levels measured by flow cytometry in cells treated with E (5 μM) or DPI (25 μM), an inhibitor of NADPH oxidase known to decrease an intracellular level of ROS, or untreated (CTR) cells. …”